Skip to main content
Back
TSUSF logo

Tsuruha Holdings Inc.

Data quality: 100%
Overbought
TSUSF
OTC Healthcare Medical - Pharmaceuticals
$17.25
$0.00 (0.00%)
Mkt Cap: 4.20B
Day Range
$17.25 $17.25
52-Week Range
$11.00 $17.25
Volume
100
50D / 200D Avg
$17.25 / $14.41
Prev Close
$17.25

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.2 0.4
P/B 0.0 2.9
ROE % 7.7 3.8
Net Margin % 2.0 3.9
Rev Growth 5Y % 3.9 10.0
D/E 0.2 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $194.21
$188.78 – $200.29
 2800 B 1
FY2029 $144.94
$140.89 – $149.47
 2700 B 1
FY2028 $129.07
$125.46 – $133.11
 2600 B 1

Key Takeaways

Revenue grew 3.91% annually over 5 years — modest growth
Debt/Equity of 0.23 — conservative balance sheet
Generating 44.53B in free cash flow
P/E of 0.19 — trading at a low valuation
Cash machine — converts 204.21% of earnings into free cash flow
Capital efficient — spends only 1.88% of revenue on capex

Growth

Revenue Growth (5Y)
3.91%
Revenue (1Y)4.30%
Earnings (1Y)-9.53%
FCF Growth (3Y)N/A

Quality

Return on Equity
7.71%
ROIC10.41%
Net Margin2.03%
Op. Margin4.48%

Safety

Debt / Equity
0.23
Current Ratio1.47
Interest Coverage26.12

Valuation

P/E Ratio
0.19
P/B Ratio0.01
EV/EBITDA-0.51
Dividend Yield0.18%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.30% Revenue Growth (3Y) 5.11%
Earnings Growth (1Y) -9.53% Earnings Growth (3Y) -7.08%
Revenue Growth (5Y) 3.91% Earnings Growth (5Y) -4.56%
Profitability
Revenue (TTM) 1.07T Net Income (TTM) 21.81B
ROE 7.71% ROA 3.74%
Gross Margin 30.46% Operating Margin 4.48%
Net Margin 2.03% Free Cash Flow (TTM) 44.53B
ROIC 10.41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.23 Current Ratio 1.47
Interest Coverage 26.12 Dividend Yield 0.18%
Valuation
P/E Ratio 0.19 P/B Ratio 0.01
P/S Ratio 0.00 PEG Ratio -0.39
EV/EBITDA -0.51 Dividend Yield 0.18%
Market Cap 4.20B Enterprise Value -24.65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.07T 1.03T 970.08B 915.70B 919.30B
Net Income 21.81B 24.11B 25.26B 21.39B 26.28B
EPS (Diluted) 448.23 493.47 89.45 103.70 87.84
Gross Profit 326.40B 312.28B 293.36B 271.48B 266.72B
Operating Income 48.03B 49.21B 45.57B 40.57B 48.38B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 583.36B 549.22B 539.83B 562.36B 537.03B
Total Liabilities 276.98B 241.48B 235.69B 278.32B 260.50B
Shareholders' Equity 282.10B 283.94B 281.58B 260.30B 254.62B
Total Debt 63.76B 50.04B 54.86B 55.52B 55.46B
Cash & Equivalents 92.61B 58.69B 58.69B 127.03B 127.03B
Current Assets 302.81B 273.85B 285.29B 328.51B 309.78B
Current Liabilities 206.65B 181.23B 181.36B 213.61B 210.22B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#90 of 820
65
Value Defensive Investing (Benjamin Graham)
#295 of 708
33

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026